MedTrace Logo

Evaluation of CEMIP in Pancreatic Cancer

NCT03679910 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2018-09-21

No results posted yet for this study

Summary

Pancreatic cancer (PC) is one of the most lethal diseases among all cancer types.

The diagnosis of PC is usually based on radiology or invasive endoscopic techniques. Various types of tumor markers are used for diagnosing PC. The tumor markers carbohydrate antigen19-9 (CA 19-9) and carcinoembryonic antigen (CEA) are the ones most closely tied to PC. These tests are more often used in people already diagnosed with pancreatic cancer to help tell if treatment is working or if the cancer is progressing .

Cell migration inducing protein (CEMIP) has been reported to be associated with early detection, cancer cell migration, invasion, and poor prognosis.

Aim of the work:

* To Estimate the level of CEMIP, CA19-9 and CEA in pancreatic cancer patients.
* To evaluate the clinical utility of serum CEMIP, CA19-9 and CEA in pancreatic cancer patients in comparison with healthy controls and their relation to cancer staging and histopathological types.
* To detect the correlation between CEMIP, CA-19-9 and CEA.

Conditions

  • Pancreas Cancer

Interventions

DIAGNOSTIC_TEST

CEMIP , CA19-9 ,CEA

CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen

DIAGNOSTIC_TEST

A) CBC . B) RBG. C)KFT. D) LFT.

A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ahmed Kamel, MD · Assiut University

  • Omnia Abd El Monaem, MD · Assiut University

  • Randa Ahmed, MD · Assiut University

  • Dina Mohammed, Dr · Assiut University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-01-01
Completion
2020-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03679910 on ClinicalTrials.gov